Premium
Apalutamide for the treatment of non‐metastatic prostate cancer
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1795
Subject(s) - medicine , prostate cancer , oncology , disease , cancer
Apalutamide (Erleada) is a selective androgenreceptor inhibitor licensed for the treatment of nonmetastatic castrationresistant prostate cancer in men who are at high risk of developing metastatic disease. This article discusses its properties, efficacy and side‐effects.